Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants With Congenital Adrenal Hyperplasia Including a Long-Term Extension

Next Previous
Trial Profile

A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants With Congenital Adrenal Hyperplasia Including a Long-Term Extension

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 11 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atumelnant (Primary)
  • Indications Congenital adrenal hyperplasia
  • Focus Registrational; Therapeutic Use
  • Acronyms Balance-CAH
  • Sponsors Crinetics Pharmaceuticals

Most Recent Events

  • 11 Feb 2026 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
  • 22 Jan 2026 According to a Crinetics Pharmaceuticals media release, company has announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial.
  • 13 Jan 2026 Planned initiation date changed (estimated date of first patient enrollment) from 30 Nov 2025 to 31 Jan 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top